Skip to Content
Søk Menu

Highlights From the Nordic Urothelial Cancer Oncology Group (NUCOG)

/ Katrine Ørum / Helle Pappot / Anders Ullén
Blærekreft
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blærekreft Play the Video

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Blærekreft
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25BlærekreftType 2-diabetes Play the Video
Peter J. Goebell

Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

/ Peter J. Goebell
ASCOGU25Blærekreft Play the Video
Helen Moon

Influence of Tumor Burden on Treatment Strategies and Clinical Outcomes in LA/mUC Patients Receiving Avelumab First-Line Maintenance: Insights from Real-World Data

/ Helen Moon
ASCOGU25Blærekreft Play the Video
Interview With Thomas Powles

Maximizing the Tolerability of Enfortumab Vedotin + Pembrolizumab – The Upcoming New Standard Treatment for Advanced Bladder Cancer

/ Thomas Powles
Blærekreft Play the Video

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
BlærekreftESMO24NyresykdomProstatakreft

Bladder Cancer: The Danish TOMBOLA Shows Practice Changing Results

/ BestPractice Nordic
BlærekreftESMO24
Jørgen Bjerggaard Jensen

ctDNA-Guided Immunotherapy Shows Promising Results to Reduce Overtreatment and Improve Outcomes for Patients with Bladder Cancer

/ Jørgen Bjerggaard Jensen
BlærekreftESMO24 Play the Video
Jeanny B. Aragon-Ching

The Landscape of Treatment for Bladder Cancer Is Changing

/ Jeanny B. Aragon-Ching
Blærekreft Play the Video
Jeanny B. Aragon-Ching

Optimal Patient Population in the JAVELIN Bladder 100-trial

/ Jeanny B. Aragon-Ching
Blærekreft Play the Video
Hent flere
Back to top